Data Insights

CBP-1008 by Coherent Biopharma for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

CBP-1008 by Coherent Biopharma for Pancreatic Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Pancreatic Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

CBP-1008 by Coherent Biopharma for Breast Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Breast Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Triple-Negative Breast Cancer (TNBC)

Data Insights

CBP-1008 by Coherent Biopharma for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

CBP-1008 by Coherent Biopharma for Lung Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Lung Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Cervical Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Cervical Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Colon Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Colon Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Colon Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Gastric Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Gastric Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Endometrial Cancer: Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Endometrial Cancer

Data Insights

CBP-1008 by Coherent Biopharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma)